These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 19166443)

  • 61. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
    Parhofer KG
    Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Nicotinic acid + larodiorant. Laropiprant adds its own adverse effects.
    Prescrire Int; 2010 Feb; 19(105):9-11. PubMed ID: 20455330
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice.
    Dänschel W; Steinhagen-Thiessen E; Buffleben C; Pittrow D; Hildemann SK
    Curr Med Res Opin; 2013 Jan; 29(1):33-40. PubMed ID: 23157464
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia.
    Keenan JM
    J Clin Lipidol; 2013; 7(1):14-23. PubMed ID: 23351578
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of extended-release niacin with laropiprant in high-risk patients.
    ; Landray MJ; Haynes R; Hopewell JC; Parish S; Aung T; Tomson J; Wallendszus K; Craig M; Jiang L; Collins R; Armitage J
    N Engl J Med; 2014 Jul; 371(3):203-12. PubMed ID: 25014686
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
    Farnier M; Freeman MW; Macdonell G; Perevozskaya I; Davies MJ; Mitchel YB; Gumbiner B;
    Eur Heart J; 2005 May; 26(9):897-905. PubMed ID: 15781429
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).
    Zhao XQ; Morse JS; Dowdy AA; Heise N; DeAngelis D; Frohlich J; Chait A; Albers JJ; Brown BG
    Am J Cardiol; 2004 Feb; 93(3):307-12. PubMed ID: 14759379
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
    Mohiuddin SM; Pepine CJ; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
    Am Heart J; 2009 Jan; 157(1):195-203. PubMed ID: 19081418
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety of niacin and simvastatin combination therapy.
    Bays H
    Am J Cardiol; 2008 Apr; 101(8A):3B-8B. PubMed ID: 18375239
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV
    Int J Clin Pract; 2007 Nov; 61(11):1942-8. PubMed ID: 17935553
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.
    Yeganeh B; Moshtaghi-Kashanian GR; Declercq V; Moghadasian MH
    J Nutr Biochem; 2005 Apr; 16(4):222-8. PubMed ID: 15808326
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Niacin use and cutaneous flushing: mechanisms and strategies for prevention.
    Davidson MH
    Am J Cardiol; 2008 Apr; 101(8A):14B-19B. PubMed ID: 18375236
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
    Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet.
    Ose L; Johnson-Levonas A; Reyes R; Lin J; Shah A; Tribble D; Musliner T;
    Int J Clin Pract; 2007 Sep; 61(9):1469-80. PubMed ID: 17655686
    [TBL] [Abstract][Full Text] [Related]  

  • 78. New perspectives on the use of niacin in the treatment of lipid disorders.
    McKenney J
    Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women.
    Goldberg AC
    Am J Cardiol; 2004 Jul; 94(1):121-4. PubMed ID: 15219522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.